TLDR Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
The theoretical research evaluated the interaction of twenty cannabinoid derivatives with either androgen receptor or 5a-reductase enzyme. The results showed that cannabinoid derivatives 6, 13, 16, and 20 had higher affinity for the androgen receptor surface compared to testosterone, dihydrotestosterone, and flutamide. Additionally, cannabinoid derivatives 1, 3, 14, and 18 showed higher affinity for the 5a-reductase enzyme compared to dutasteride and finasteride. This suggests that these cannabinoid derivatives could act as androgen receptor inhibitors and 5a-reductase enzyme inhibitors, making them potential candidates for the treatment of prostate cancer.
5 citations,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
30 citations,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
November 2023 in “Frontiers in Neuroendocrinology” Some people experience lasting sexual, psychological, and sleep problems after using finasteride or SSRI antidepressants, possibly due to similar underlying causes.
20 citations,
November 2019 in “Biomolecules” Finasteride reduces response to stress and rewards, affecting behavior and mental health.
97 citations,
March 2009 in “Dermato-endocrinology” Hormones significantly affect hair and oil gland function in the skin, and more research is needed on skin-related hormone disorders.
3 citations,
December 2022 in “Cells” Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.
14 citations,
April 2014 in “International Journal of Cosmetic Science” Acne is caused by multiple factors including oil production, bacteria, inflammation, and possibly diet and environment.
